Trends in Medications for Autoimmune Disorders During Pregnancy and Factors for Their Discontinuation: a Population-based Study

Overview

Journal BMC Pregnancy Childbirth

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2024 Nov 20

PMID 39563243

Authors

Sabine Mainbourg

Odile Sheehy

Jessica Gorgui

Evelyne Vinet

Anick Berard

Affiliations

Soon will be listed here.

Abstract

Objectives: The medications used for autoimmune diseases have significantly evolved in recent years, but there is limited knowledge about how treatment practices changed during pregnancy. This study aimed to describe the temporal trends of immunosuppressants, immunomodulators and biologics use during pregnancy among women with autoimmune diseases, compare their use before, during, and after pregnancy, and identify factors predicting the discontinuation of these medications during pregnancy.

Methods: Using data from the Quebec Pregnancy Cohort (1998-2015), which included women under the RAMQ prescription drug plan for at least 12 months before and after pregnancy, the analysis focused on those with at least one International Classification of Diseases Ninth or Tenth Revision code in the year before pregnancy for inflammatory bowel disease, rheumatoid arthritis, spondylarthropathies, connective tissue diseases, systemic lupus erythematosus, or vasculitis. Exposure to immunosuppressants, immunomodulators and biologics were evaluated before and during the pregnancy. Discontinuation during pregnancy was defined as having no prescriptions filled during pregnancy or overlapping with the first day of gestation (1DG), given that at least one prescription was filled in the year prior to pregnancy. Generalized estimating equations were applied to estimate adjusted odds ratios (aOR) for predicting medication discontinuation during pregnancy.

Results: Among 441,570 pregnant women, 3,285 had autoimmune diseases. From 1998 to 2014, the use of immunomodulators increased from 3.7% to 11.9%, immunosuppressants from 4.1% to 13.7%, and biologics from 0% to 15.6%. During pregnancy, compared to before, there was a significant decrease in exposure to immunomodulators (8.6% to 5.4%), immunosuppressants (14.2% to 8.7%), and biologics (5.1% to 4.7%). Factors influencing discontinuation varied by medication type; for immunosuppressants, prior biologics use (aOR = 2.12, 95%CI 1.16-3.85) and the year of pregnancy (aOR = 0.93, 95%CI 0.89-0.98) were key factors, while for biologics, it was only the year of pregnancy (aOR = 0.68, 95%CI 0.54-0.86).

Conclusions: The use of immunomodulators, immunosuppressants, and biologics has increased over time. However, exposure during pregnancy decreased, with recent years showing a lower rate of discontinuation. Understanding the factors influencing medication discontinuation during pregnancy can improve management strategies for women with autoimmune diseases.

References

Ward M, Deodhar A, Gensler L, Dubreuil M, Yu D, Khan M . 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019; 71(10):1599-1613. PMC: 6764882. DOI: 10.1002/art.41042. View

Scott I, Whittle R, Bailey J, Twohig H, Hider S, Mallen C . Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg Health Eur. 2022; 23:100519. PMC: 9557034. DOI: 10.1016/j.lanepe.2022.100519. View

Albrecht K, Redeker I, Aringer M, Marschall U, Strangfeld A, Callhoff J . Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. Lupus Sci Med. 2021; 8(1). PMC: 8388287. DOI: 10.1136/lupus-2021-000526. View

Gerbier E, Graber S, Rauch M, Marxer C, Meier C, Baud D . Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data. Int J Environ Res Public Health. 2022; 19(3). PMC: 8835338. DOI: 10.3390/ijerph19031456. View

Tsao N, Lynd L, Sadatsafavi M, Hanley G, De Vera M . Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2017; 70(7):979-986. DOI: 10.1002/acr.23434. View

Hyoun S, Obican S, Scialli A . Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012; 94(4):187-207. DOI: 10.1002/bdra.23003. View

Fernandez-Buhigas I . Obstetric management of the most common autoimmune diseases: A narrative review. Front Glob Womens Health. 2022; 3:1031190. PMC: 9728613. DOI: 10.3389/fgwh.2022.1031190. View

Berard A, Sheehy O . The Quebec Pregnancy Cohort--prevalence of medication use during gestation and pregnancy outcomes. PLoS One. 2014; 9(4):e93870. PMC: 3976411. DOI: 10.1371/journal.pone.0093870. View

Goldblatt F, ONeill S . Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013; 382(9894):797-808. DOI: 10.1016/S0140-6736(13)61499-3. View

10.

Chen C, Wang L, Wei W, Yuce H, Phillips K . Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2019; 2(1):rky005. PMC: 6649951. DOI: 10.1093/rap/rky005. View

11.

Chambers C, Johnson D, Xu R, Luo Y, Lopez-Jimenez J, Adam M . Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS One. 2019; 14(10):e0223603. PMC: 6799916. DOI: 10.1371/journal.pone.0223603. View

12.

Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S . EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2023; 83(1):15-29. DOI: 10.1136/ard-2023-224762. View

13.

Atzeni F, Defendenti C, Ditto M, Batticciotto A, Ventura D, Antivalle M . Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):20-3. DOI: 10.1016/j.autrev.2013.06.006. View

14.

Ostensen M, Forger F . Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009; 5(7):382-90. DOI: 10.1038/nrrheum.2009.103. View

15.

Desai R, Huybrechts K, Bateman B, Hernandez-Diaz S, Mogun H, Gopalakrishnan C . Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis Rheumatol. 2015; 68(5):1183-9. PMC: 4848128. DOI: 10.1002/art.39521. View

16.

Vilain A, Otis S, Forget A, Blais L . Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf. 2008; 17(4):345-53. DOI: 10.1002/pds.1558. View

17.

Bernstein C, Nugent Z, Shaffer S, Singh H, Marrie R . Comorbidity before and after a diagnosis of inflammatory bowel disease. Aliment Pharmacol Ther. 2021; 54(5):637-651. DOI: 10.1111/apt.16444. View

18.

De Vera M, Baldwin C, Tsao N, Howren A, Hazlewood G, Rebic N . Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists. BMC Rheumatol. 2019; 3:18. PMC: 6530147. DOI: 10.1186/s41927-019-0065-8. View

19.

Zhao J, Sheehy O, Gorgui J, Berard A . Can We Rely on Pharmacy Claims Databases to Ascertain Maternal Use of Medications during Pregnancy?. Birth Defects Res. 2017; 109(6):423-431. DOI: 10.1002/bdra.23604. View

20.

Thai T, Sarayani A, Wang X, Albogami Y, Rasmussen S, Winterstein A . Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2020; 29(6):716-724. DOI: 10.1002/pds.5017. View